A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naive, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast.

Trial Profile

A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naive, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Fozivudine (Primary) ; Efavirenz; Lamivudine; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FATI01; FATI1
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 19 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top